Eliquis vs. Savaysa
See how Eliquis and Savaysa compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Eliquis is taken twice daily and covers more approved uses, including surgical DVT prevention and pediatric VTE treatment.
Savaysa is a once-daily pill but is not recommended for atrial fibrillation patients with very strong kidney function.
Both drugs are factor Xa inhibitors that raise bleeding risk and carry a boxed warning against stopping treatment early.
Eliquis vs. Savaysa Drug Summary
Eliquis
Eliquis (apixaban) is a factor Xa inhibitor anticoagulant used to prevent stroke in atrial fibrillation, prevent and treat blood clots (DVT/PE), and reduce clot risk after hip or knee replacement. It is taken as a tablet twice a day, with dosing that varies by indication and patient risk factors.
Savaysa
Savaysa (edoxaban) is a factor Xa inhibitor anticoagulant used to prevent stroke in atrial fibrillation and to treat DVT and PE. It is taken as a single tablet once a day, usually after several days of an injectable blood thinner when starting treatment for DVT or PE.
Eliquis vs. Savaysa Side Effects
Eliquis
Savaysa
Eliquis vs. Savaysa Dosage
Eliquis
Savaysa
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg twice daily | Days 1-7 |
| Maximum dose | 2.5 mg twice daily | If needed |
| Dose changes | 1 increase | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 30 mg once daily | At the start |
| Maximum dose | 30 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Eliquis
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg twice daily | Days 1-7 |
| Maximum dose | 2.5 mg twice daily | If needed |
| Dose changes | 1 increase | As tolerated |
Savaysa
| STAGE | DOSE | WHEN |
| Starting dose | 30 mg once daily | At the start |
| Maximum dose | 30 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Eliquis vs. Savaysa Indications
Eliquis
Eliquis is FDA-approved for a broad range of clotting conditions, from stroke prevention in atrial fibrillation to surgical clot prevention and pediatric clot treatment. It also carries the widest age range of any oral factor Xa inhibitor, with pediatric dosing approved from birth.
Reduce stroke and systemic embolism risk in nonvalvular AFib
Prevent DVT after hip or knee replacement surgery
Treat DVT and PE
Savaysa
Savaysa is FDA-approved for stroke prevention in atrial fibrillation and for treating DVT and PE in adults. It is not approved for surgical clot prevention, pediatric use, or patients with very strong kidney function.
Reduce stroke and systemic embolism risk in nonvalvular AFib
Treat deep vein thrombosis (DVT)
Treat pulmonary embolism (PE)
Eliquis vs. Savaysa Pros and Cons
Eliquis
Eliquis covers more approved uses than Savaysa, including surgical DVT prevention and pediatric clot treatment, and it has a specific reversal agent available for bleeding emergencies. The tradeoff is a twice-daily pill instead of a once-daily one.
Pros
Approved for DVT prevention after hip or knee surgery
Approved for pediatric VTE treatment from birth
No restriction based on excellent kidney function
Cons
Must be taken twice a day instead of once
Requires dose adjustment across multiple criteria (age, weight, kidney function)
Carries a boxed warning about spinal or epidural blood clots during certain procedures
Savaysa
Savaysa offers the convenience of one pill a day, but it comes with a boxed warning against use in atrial fibrillation patients whose kidneys clear the drug too efficiently. It also covers fewer approved indications than Eliquis.
Pros
Only needs to be taken once a day
Simpler two-dose maintenance schedule (60 mg or 30 mg)
No initial loading-dose titration needed
Cons
Not recommended for AFib patients with CrCL above 95 mL/min
Not approved for surgical clot prevention or pediatric use
Requires 5 to 10 days of injectable anticoagulant before starting for DVT/PE
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.